Payment overview · 2025
General Payments
$423.83
31 reported records · 11 companies
Healthcare provider profile · identity verified
Kimberly D Roller, MD
Allopathic & Osteopathic Physicians|Family Medicine · KINGSPORT, TN · NPI 1457544868
Verified facts
What the public records show
CMS Open Payments records show Kimberly D Roller, MD received $423.83 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.85 | 39.4% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.38 | 14.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.60 | 11.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.44 | 7.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.89 | 5.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.56 | 4.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.84 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.54 | 3.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.51 | 3.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.80 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.42 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $423.83 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $146.00 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.65 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.38 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.38 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 309 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
309 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
309 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 638 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 459 | 129 |
| Losartan Potassium | Losartan Potassium | 445 | 119 |
| Lisinopril | Lisinopril | 412 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 359 | 90 |
| Gabapentin | Gabapentin | 328 | 67 |
| Eliquis | Apixaban | 309 | 52 |
| Omeprazole | Omeprazole | 268 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 249 | 65 |
| Furosemide | Furosemide | 244 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 64 |
| Alprazolam | Alprazolam | 199 | 32 |
| Metformin Hcl | Metformin Hcl | 193 | 51 |
| Potassium Chloride | Potassium Chloride | 178 | 52 |
| Simvastatin | Simvastatin | 175 | 48 |
| Meloxicam | Meloxicam | 168 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 39 |
| Montelukast Sodium | Montelukast Sodium | 135 | 35 |
| Buspirone Hcl | Buspirone Hcl | 131 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 57 |
| Prednisone | Prednisone | 123 | 73 |
| Warfarin Sodium | Warfarin Sodium | 113 | 21 |
| Glipizide Er | Glipizide | 106 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 22 |
| Trazodone Hcl | Trazodone Hcl | 103 | 29 |
| Allopurinol | Allopurinol | 101 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 28 |
| Metformin Hcl Er | Metformin Hcl | 91 | 26 |
| Carvedilol | Carvedilol | 89 | 24 |
| Tramadol Hcl | Tramadol Hcl | 86 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 22 |
| Alendronate Sodium | Alendronate Sodium | 85 | 18 |
| Lorazepam | Lorazepam | 85 | 12 |
| Sertraline Hcl | Sertraline Hcl | 81 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 20 |
| Famotidine | Famotidine | 72 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 19 |
| Ozempic | Semaglutide | 70 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 60 |
| Diltiazem 24hr Er | Diltiazem Hcl | 67 | 21 |
| Atenolol | Atenolol | 62 | 17 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Glimepiride | Glimepiride | 61 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 14 |
| Donepezil Hcl | Donepezil Hcl | 59 | 17 |
| Synthroid | Levothyroxine Sodium | 59 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 12 |
| Spironolactone | Spironolactone | 54 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Estradiol | Estradiol | 52 | 20 |
| Ibuprofen | Ibuprofen | 51 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 13 |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Irbesartan | Irbesartan | 44 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 31 |
| Fosinopril Sodium | Fosinopril Sodium | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Cephalexin | Cephalexin | 37 | 29 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 37 | 11 |
| Clonidine Hcl | Clonidine Hcl | 36 | 11 |
| Temazepam | Temazepam | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 11 |
| Baclofen | Baclofen | 34 | 13 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 17 |
| Methocarbamol | Methocarbamol | 32 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 22 |
| Fluconazole | Fluconazole | 24 | 21 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Amoxicillin | Amoxicillin | 23 | 16 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | 12 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 14 |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $423.83 · 31 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, Heplisav-B, JARDIANCE, Kerendia, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error